Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diantican sodium
- Development stage
- Phase 1
- Lead developer
- Fangsheng Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Diantican sodium (FS-1101) is a novel, water-soluble camptothecin derivative developed by Hunan Fangsheng Pharmaceutical. It functions as a DNA topoisomerase I (TOP1) inhibitor, a class of drugs that interferes with the DNA replication process by stabilizing the TOP1-DNA cleavable complex. This stabilization prevents the re-ligation of DNA strands, resulting in permanent double-strand breaks and subsequent cell death. Diantican sodium is being developed for the treatment of advanced solid tumors, with a focus on colorectal, gastric, breast, and lung cancers. It aims to provide a more favorable solubility and safety profile compared to existing camptothecin analogues like irinotecan.
- Other names
- Dian-Ti-Can sodium典替康钠
Beyond the preview
Go deeper on diantican sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diantican sodium.